Accelerate Diagnostics Stock Price, News & Analysis (NASDAQ:AXDX)

$24.95 +0.40 (+1.63 %)
(As of 02/21/2018 04:00 PM ET)
Previous Close$24.55
Today's Range$24.70 - $25.80
52-Week Range$16.75 - $30.45
Volume215,664 shs
Average Volume285,028 shs
Market Capitalization$1.40 billion
P/E Ratio-21.51
Dividend YieldN/A
Beta2.2

About Accelerate Diagnostics (NASDAQ:AXDX)

Accelerate Diagnostics logoAccelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

Receive AXDX News and Ratings via Email

Sign-up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AXDX
CUSIPN/A
Phone520-365-3100

Debt

Debt-to-Equity RatioN/A
Current Ratio21.24%
Quick Ratio20.06%

Price-To-Earnings

Trailing P/E Ratio-21.5084352721097
Forward P/E Ratio-19.96
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.18 million
Price / Sales332.29
Cash FlowN/A
Price / CashN/A
Book Value$1.51 per share
Price / Book16.52

Profitability

Trailing EPS($1.16)
Net Income$-62,880,000.00
Net Margins-1,520.99%
Return on Equity-55.26%
Return on Assets-52.54%

Miscellaneous

EmployeesN/A
Outstanding Shares55,670,000

Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics Inc (NASDAQ:AXDX) posted its quarterly earnings data on Thursday, February, 15th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.33) by $0.06. The medical research company had revenue of $2.10 million for the quarter. Accelerate Diagnostics had a negative net margin of 1,520.99% and a negative return on equity of 55.26%. View Accelerate Diagnostics' Earnings History.

Where is Accelerate Diagnostics' stock going? Where will Accelerate Diagnostics' stock price be in 2018?

2 brokerages have issued 12 month price objectives for Accelerate Diagnostics' shares. Their predictions range from $32.00 to $34.00. On average, they expect Accelerate Diagnostics' share price to reach $33.00 in the next twelve months. View Analyst Ratings for Accelerate Diagnostics.

What are Wall Street analysts saying about Accelerate Diagnostics stock?

Here are some recent quotes from research analysts about Accelerate Diagnostics stock:

  • 1. BTIG Research analysts commented, "Outlook Remains The Same As the company preannounced Q4 revenue and provided FY18 revenue expectations on January 10th , the company’s formal earnings call was fairly straightforward without surprises. The messaging was largely consistent with what we learned from the company’s JPM conference presentation though we now may expect an update on progress with the FDA on the LRTI test as early as the Q1 call. Overall, we remain very positive on the technology and the total opportunity but feel the company needs to consistently hit estimates through the course of the year for the Street to regain comfort with the model. We maintain our Neutral rating.   Modestly tweaking our estimates for gross margin. Our revenue estimates are unchanged but we have increased our gross margin estimates to reflect better trends in Q4. Our full year FY18 revenue estimate is $25M and we assume roughly 2/3 of revenue will be recognized in the 2H. For Q1, we model a slight uptick sequentially from Q4 revenue of $2.12M to $3.2M; of note, this estimate also seems to be lower than other estimates on the Street of $4-5M. Given the timing of hospital purchasing, we prefer to have a conservative bias in the start of the year.   Valuation: Shares are Neutral rated based on our DCF analysis. Risks follow." (2/18/2018)
  • 2. According to Zacks Investment Research, "Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, a rapid diagnostic platform for diagnosis in life-threatening bacterial infections and OptiChem(R) surface coatings for use in micro arraying components. Accelerate Diagnostics Inc., formerly known as Accelr8 Technology Corp., is based in Denver, Colorado. " (1/15/2018)

Who are some of Accelerate Diagnostics' key competitors?

Who are Accelerate Diagnostics' key executives?

Accelerate Diagnostics' management team includes the folowing people:

  • John Patience, Independent Chairman of the Board (Age 69)
  • Lawrence Mehren, President, Chief Executive Officer, Director (Age 50)
  • Steve Reichling, Chief Financial Officer (Age 38)
  • Joan Martin, Executive Vice President & Head of Europe, Middle East, and Africa (Age 48)
  • Ron Price, Senior Vice President and Head of Commercial Operations, Americas (Age 53)
  • Charles Watts, Director
  • Tom Brown, Independent Director (Age 68)
  • Mark C. Miller, Independent Director (Age 61)
  • Jack W. Schuler, Independent Director (Age 76)
  • Matthew W. Strobeck Ph.D., Independent Director (Age 44)

Who owns Accelerate Diagnostics stock?

Accelerate Diagnostics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.04%), ArrowMark Colorado Holdings LLC (1.69%), Next Century Growth Investors LLC (1.19%), First Republic Investment Management Inc. (1.10%), Artal Group S.A. (0.90%) and Kornitzer Capital Management Inc. KS (0.79%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, Lawrence Mehren, Matthew Strobeck and Steven Reichling. View Institutional Ownership Trends for Accelerate Diagnostics.

Who sold Accelerate Diagnostics stock? Who is selling Accelerate Diagnostics stock?

Accelerate Diagnostics' stock was sold by a variety of institutional investors in the last quarter, including Miura Global Management LLC, AXA, Kornitzer Capital Management Inc. KS, Selkirk Management LLC, First Republic Investment Management Inc., Metropolitan Life Insurance Co. NY, TIAA CREF Investment Management LLC and Wells Fargo & Company MN. Company insiders that have sold Accelerate Diagnostics company stock in the last year include Lawrence Mehren and Steven Reichling. View Insider Buying and Selling for Accelerate Diagnostics.

Who bought Accelerate Diagnostics stock? Who is buying Accelerate Diagnostics stock?

Accelerate Diagnostics' stock was bought by a variety of institutional investors in the last quarter, including Artal Group S.A., Deutsche Bank AG, Amundi Pioneer Asset Management Inc., Next Century Growth Investors LLC, Lombard Odier Asset Management USA Corp, Baird Financial Group Inc., ArrowMark Colorado Holdings LLC and SeaCrest Wealth Management LLC. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler and Matthew Strobeck. View Insider Buying and Selling for Accelerate Diagnostics.

How do I buy Accelerate Diagnostics stock?

Shares of Accelerate Diagnostics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Accelerate Diagnostics' stock price today?

One share of Accelerate Diagnostics stock can currently be purchased for approximately $24.95.

How big of a company is Accelerate Diagnostics?

Accelerate Diagnostics has a market capitalization of $1.40 billion and generates $4.18 million in revenue each year. The medical research company earns $-62,880,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]


MarketBeat Community Rating for Accelerate Diagnostics (AXDX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  124 (Vote Underperform)
Total Votes:  258
MarketBeat's community ratings are surveys of what our community members think about Accelerate Diagnostics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Accelerate Diagnostics (NASDAQ:AXDX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.503.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $33.00$33.00$33.00$33.00
Price Target Upside: 31.21% upside10.00% upside17.65% upside17.65% upside

Accelerate Diagnostics (NASDAQ:AXDX) Consensus Price Target History

Price Target History for Accelerate Diagnostics (NASDAQ:AXDX)

Accelerate Diagnostics (NASDAQ:AXDX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/18/2018BTIG ResearchReiterated RatingHoldMediumView Rating Details
6/5/2017Piper Jaffray CompaniesReiterated RatingOverweight$30.00 -> $32.00LowView Rating Details
8/9/2016JPMorgan Chase & Co.Boost Price TargetOverweight$17.00 -> $25.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Accelerate Diagnostics (NASDAQ:AXDX) Earnings History and Estimates Chart

Earnings by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Accelerate Diagnostics (NASDAQ AXDX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/15/2018Q4 2017($0.33)($0.27)$2.10 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.32)($0.31)$2.78 million$0.83 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.30)($0.31)$1.40 million$0.70 millionViewListenView Earnings Details
5/5/2017Q1($0.34)($0.27)$0.60 million$0.50 millionViewListenView Earnings Details
2/27/2017Q4 2016($0.35)($0.31)$0.24 million$0.04 millionViewListenView Earnings Details
11/9/2016Q3 2016($0.35)($0.34)$0.02 millionViewN/AView Earnings Details
8/8/2016Q2 2016($0.32)($0.35)$0.02 millionViewN/AView Earnings Details
5/10/2016Q1 2016($0.26)($0.29)$0.04 million$0.16 millionViewN/AView Earnings Details
3/9/2016Q4 2015($0.29)$0.02 millionViewN/AView Earnings Details
11/2/2015Q3 2015($0.25)$0.09 millionViewN/AView Earnings Details
7/31/2015Q2 2015($0.27)$0.02 millionViewN/AView Earnings Details
5/7/2015Q1 2015($0.20)$0.01 millionViewN/AView Earnings Details
2/26/2015Q4 2014($0.20)$0.08 millionViewN/AView Earnings Details
11/4/2014Q3 2014($0.20)$0.02 millionViewN/AView Earnings Details
8/1/2014Q2 2014($0.19)$0.01 millionViewN/AView Earnings Details
5/2/2014Q1 2014($0.12)$0.01 millionViewN/AView Earnings Details
3/7/2014Q4 2013($0.13)$0.01 millionViewN/AView Earnings Details
11/8/2013Q3 2013($0.10)$0.01 millionViewN/AView Earnings Details
8/9/2013Q2 2013($0.13)$0.01 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.09)$0.02 millionViewN/AView Earnings Details
12/14/2012Q4 2012($0.06)ViewN/AView Earnings Details
10/26/2012Q3 2012($0.33)ViewN/AView Earnings Details
6/13/2012Q2 2012($0.03)ViewN/AView Earnings Details
3/15/2012Q1 2012($0.03)ViewN/AView Earnings Details
12/14/2011Q4 2011($0.04)ViewN/AView Earnings Details
10/27/2011Q3 2011($0.03)ViewN/AView Earnings Details
9/17/2010Q3 2010$0.17ViewN/AView Earnings Details
6/16/2008Q2 2008($0.04)ViewN/AView Earnings Details
3/17/2008Q1 2008($0.03)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Accelerate Diagnostics (NASDAQ:AXDX) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.25 EPS
Next Year EPS Consensus Estimate: $-0.53 EPS

Dividends

Dividend History for Accelerate Diagnostics (NASDAQ:AXDX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Accelerate Diagnostics (NASDAQ AXDX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 50.00%
Institutional Ownership Percentage: 47.21%
Insider Trades by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)
Institutional Ownership by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Accelerate Diagnostics (NASDAQ AXDX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2017Jack W SchulerDirectorBuy5,500$22.00$121,000.00View SEC Filing  
11/15/2017Jack W SchulerDirectorBuy20,000$20.00$400,000.00View SEC Filing  
11/13/2017Jack W SchulerDirectorBuy20,000$18.98$379,600.00View SEC Filing  
11/10/2017Jack W SchulerDirectorBuy51,181$18.67$955,549.27View SEC Filing  
11/8/2017Jack W SchulerDirectorBuy50,000$18.46$923,000.00View SEC Filing  
11/6/2017Jack W SchulerDirectorBuy340,964$18.51$6,311,243.6444,670View SEC Filing  
10/18/2017Jack W SchulerDirectorBuy45,000$20.14$906,300.00View SEC Filing  
10/16/2017Jack W SchulerDirectorBuy59,922$20.07$1,202,634.54View SEC Filing  
10/13/2017Jack W SchulerDirectorBuy61,300$19.29$1,182,477.00View SEC Filing  
10/12/2017Jack W SchulerDirectorBuy276,200$19.74$5,452,188.00View SEC Filing  
10/11/2017Jack W SchulerDirectorBuy51,600$20.27$1,045,932.00View SEC Filing  
8/21/2017Jack W SchulerDirectorBuy50,000$21.45$1,072,500.00View SEC Filing  
8/17/2017Lawrence MehrenInsiderSell223,215$22.40$5,000,016.00762,381View SEC Filing  
8/15/2017Jack W SchulerDirectorBuy8,200$21.35$175,070.00View SEC Filing  
8/14/2017Jack W SchulerDirectorBuy23,400$21.35$499,590.00View SEC Filing  
8/11/2017Jack W SchulerDirectorBuy80,000$21.43$1,714,400.00View SEC Filing  
6/21/2017Steven ReichlingInsiderSell30,000$28.90$867,000.0030,700View SEC Filing  
1/9/2017Lawrence MehrenInsiderSell400,068$19.00$7,601,292.00View SEC Filing  
1/9/2017Matthew StrobeckDirectorBuy8,000$19.00$152,000.002,045,560View SEC Filing  
6/30/2016Jack W SchulerDirectorBuy90,147$13.95$1,257,550.65View SEC Filing  
6/14/2016Jack W SchulerDirectorBuy14,033$13.67$191,831.11View SEC Filing  
6/13/2016Jack W SchulerDirectorBuy15,967$13.70$218,747.90View SEC Filing  
6/10/2016Jack W SchulerDirectorBuy88,316$14.69$1,297,362.04View SEC Filing  
6/9/2016Jack W SchulerDirectorBuy101,272$14.14$1,431,986.08View SEC Filing  
5/20/2016Jack W SchulerDirectorBuy4,270$11.04$47,140.80View SEC Filing  
5/17/2016Jack W SchulerDirectorBuy10,000$11.45$114,500.00View SEC Filing  
5/16/2016Jack W SchulerDirectorBuy11,511$11.91$137,096.01View SEC Filing  
5/13/2016Jack W SchulerDirectorBuy20,000$12.45$249,000.00View SEC Filing  
2/9/2016Jack W SchulerDirectorBuy600,000$11.86$7,116,000.00View SEC Filing  
2/8/2016Jack W SchulerDirectorBuy20,000$12.32$246,400.00View SEC Filing  
2/5/2016Jack W SchulerDirectorBuy7,308$12.65$92,446.20View SEC Filing  
2/4/2016Jack W SchulerDirectorBuy10,000$12.98$129,800.00View SEC Filing  
2/3/2016Jack W SchulerDirectorBuy50,100$13.09$655,809.00View SEC Filing  
2/2/2016Jack W SchulerDirectorBuy20,000$13.46$269,200.00View SEC Filing  
1/21/2016Jack W SchulerDirectorBuy10,000$15.02$150,200.00View SEC Filing  
12/10/2015Larry N FeinbergMajor ShareholderBuy117,647$17.00$1,999,999.00173,079View SEC Filing  
11/5/2015Jack W SchulerDirectorBuy11,899$16.81$200,022.19View SEC Filing  
11/4/2015Jack W SchulerDirectorBuy52,837$16.81$888,189.97View SEC Filing  
10/22/2015Jack W SchulerDirectorBuy2,160$15.82$34,171.20View SEC Filing  
9/29/2015Brink Frank Jm TenDirectorBuy9,800$15.24$149,352.009,800View SEC Filing  
8/26/2015Jack W SchulerDirectorBuy10,000$17.81$178,100.00View SEC Filing  
8/25/2015Jack W SchulerDirectorBuy10,000$18.56$185,600.00View SEC Filing  
4/17/2015Jack W SchulerDirectorBuy11,000$21.94$241,340.00View SEC Filing  
3/19/2015Matthew StrobeckDirectorBuy2,000$22.04$44,080.00View SEC Filing  
3/9/2015Jack W SchulerDirectorBuy22,584$17.18$387,993.12View SEC Filing  
1/5/2015Jack W SchulerDirectorBuy18,000$18.93$340,740.00View SEC Filing  
9/22/2014Jack W SchulerDirectorBuy2,588$16.44$42,546.72View SEC Filing  
9/19/2014Jack W SchulerDirectorBuy32,411$16.67$540,291.37View SEC Filing  
8/21/2014Jack W SchulerDirectorBuy2,900$16.79$48,691.00View SEC Filing  
8/5/2014Larry N FeinbergMajor ShareholderBuy11,835$15.92$188,413.20View SEC Filing  
8/5/2014Matthew StrobeckDirectorBuy20,000$16.70$334,000.00View SEC Filing  
8/4/2014Matthew StrobeckDirectorBuy20,000$16.70$334,000.00View SEC Filing  
7/16/2014Larry N FeinbergMajor ShareholderBuy20,000$21.54$430,800.00View SEC Filing  
7/1/2014Jack W SchulerDirectorBuy8,698$25.70$223,538.60View SEC Filing  
6/30/2014Jack W SchulerDirectorBuy10,000$26.09$260,900.00View SEC Filing  
6/30/2014Larry N FeinbergMajor ShareholderBuy20,000$25.72$514,400.00View SEC Filing  
5/12/2014Larry N FeinbergMajor ShareholderBuy297,618$16.80$4,999,982.40View SEC Filing  
2/5/2014Larry N FeinbergMajor ShareholderBuy8,554$24.78$211,968.12View SEC Filing  
1/27/2014Larry N FeinbergMajor ShareholderBuy16,307$13.09$213,458.63View SEC Filing  
12/31/2013Larry N FeinbergMajor ShareholderBuy84,081$12.29$1,033,355.49View SEC Filing  
10/30/2013Larry N FeinbergMajor ShareholderBuy10,000$12.95$129,500.00View SEC Filing  
8/30/2013Larry N FeinbergMajor ShareholderBuy16,001$9.76$156,169.76View SEC Filing  
8/28/2013Larry N FeinbergMajor ShareholderBuy158,445$9.80$1,552,761.00View SEC Filing  
8/16/2013Jack W SchulerDirectorBuy78,494$7.88$618,532.72View SEC Filing  
8/14/2013Jack W SchulerDirectorBuy413,090$8.04$3,321,243.60View SEC Filing  
8/14/2013Larry N FeinbergMajor ShareholderBuy36,814$7.24$266,533.36View SEC Filing  
8/9/2013Larry N FeinbergMajor ShareholderBuy35,168$7.30$256,726.40View SEC Filing  
6/21/2013Larry N FeinbergMajor ShareholderBuy114,250$8.00$914,000.00View SEC Filing  
6/12/2013Larry N FeinbergMajor ShareholderBuy7,175$8.41$60,341.75View SEC Filing  
6/7/2013Larry N FeinbergMajor ShareholderBuy45,508$8.33$379,081.64View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Accelerate Diagnostics (NASDAQ AXDX) News Headlines

Source:
DateHeadline
Accelerate Diagnostics (AXDX) Stock Rating Lowered by BidaskClubAccelerate Diagnostics (AXDX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - February 19 at 3:38 PM
BTIG Research Reaffirms "Hold" Rating for Accelerate Diagnostics (AXDX)BTIG Research Reaffirms "Hold" Rating for Accelerate Diagnostics (AXDX)
www.americanbankingnews.com - February 18 at 3:09 PM
Notable Friday Option Activity: AXDX, NSM, ELFNotable Friday Option Activity: AXDX, NSM, ELF
www.nasdaq.com - February 16 at 4:41 PM
Accelerate Diagnostics (AXDX) Announces Quarterly  Earnings ResultsAccelerate Diagnostics (AXDX) Announces Quarterly Earnings Results
www.americanbankingnews.com - February 16 at 10:56 AM
Accelerate Diagnostics reports 4Q lossAccelerate Diagnostics reports 4Q loss
www.cnbc.com - February 16 at 9:03 AM
Accelerate Diagnostics reports Q4 and Full-Year Financial Results for 2017Accelerate Diagnostics reports Q4 and Full-Year Financial Results for 2017
finance.yahoo.com - February 15 at 4:40 PM
Stock Traders Purchase High Volume of Call Options on Accelerate Diagnostics (AXDX)Stock Traders Purchase High Volume of Call Options on Accelerate Diagnostics (AXDX)
www.americanbankingnews.com - February 14 at 9:10 PM
Accelerate Diagnostics Sees Unusually Large Options Volume (AXDX)Accelerate Diagnostics Sees Unusually Large Options Volume (AXDX)
www.americanbankingnews.com - February 11 at 1:52 AM
-$0.33 Earnings Per Share Expected for Accelerate Diagnostics Inc (AXDX) This Quarter-$0.33 Earnings Per Share Expected for Accelerate Diagnostics Inc (AXDX) This Quarter
www.americanbankingnews.com - February 10 at 3:12 PM
Accelerate Diagnostics (AXDX) Cut to "Sell" at ValuEngineAccelerate Diagnostics (AXDX) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - February 9 at 11:46 PM
Accelerate Diagnostics to Host Q4 and Full-Year 2017 Earnings Call on February 15, 2018Accelerate Diagnostics to Host Q4 and Full-Year 2017 Earnings Call on February 15, 2018
finance.yahoo.com - February 9 at 9:17 AM
Critical Contrast: Sirona Dental Systems (SIRO) and Accelerate Diagnostics (AXDX)Critical Contrast: Sirona Dental Systems (SIRO) and Accelerate Diagnostics (AXDX)
www.americanbankingnews.com - February 8 at 1:18 AM
 Accelerate Diagnostics Inc (AXDX) Given Consensus Recommendation of "Buy" by Brokerages Accelerate Diagnostics Inc (AXDX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 7 at 11:56 AM
Notable Friday Option Activity: AXDX, MSTR, LAYNNotable Friday Option Activity: AXDX, MSTR, LAYN
www.nasdaq.com - January 27 at 9:38 AM
Accelerate Diagnostics Inc (AXDX) Expected to Post Earnings of -$0.33 Per ShareAccelerate Diagnostics Inc (AXDX) Expected to Post Earnings of -$0.33 Per Share
www.americanbankingnews.com - January 24 at 3:26 PM
Reviewing Accelerate Diagnostics (AXDX) & Volcano (VOLC)Reviewing Accelerate Diagnostics (AXDX) & Volcano (VOLC)
www.americanbankingnews.com - January 21 at 5:26 AM
Accelerate Diagnostics (AXDX) Cut to "Sell" at Zacks Investment ResearchAccelerate Diagnostics (AXDX) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - January 15 at 7:28 PM
Accelerate Diagnostics Inc (AXDX) Expected to Post FY2017 Earnings of ($1.22) Per ShareAccelerate Diagnostics Inc (AXDX) Expected to Post FY2017 Earnings of ($1.22) Per Share
www.americanbankingnews.com - January 15 at 3:02 AM
Accelerate Diagnostics (AXDX) & BIOLASE (BIOL) Financial SurveyAccelerate Diagnostics (AXDX) & BIOLASE (BIOL) Financial Survey
www.americanbankingnews.com - January 13 at 3:32 AM
Accelerate Diagnostics achieves CE-IVD milestone for severe bacterial pneumonia assay, doubles revenue for 2017 in ... - GlobeNewswire (press release)Accelerate Diagnostics achieves CE-IVD milestone for severe bacterial pneumonia assay, doubles revenue for 2017 in ... - GlobeNewswire (press release)
globenewswire.com - January 11 at 3:30 PM
Accelerate Diagnostics (AXDX) Reports Prelim. Q4 Revenue of $2.1M; Achieves CE-IVD Milestone for Severe Bacterial Pneumonia AssayAccelerate Diagnostics (AXDX) Reports Prelim. Q4 Revenue of $2.1M; Achieves CE-IVD Milestone for Severe Bacterial Pneumonia Assay
www.streetinsider.com - January 11 at 9:24 AM
Accelerate Diagnostics achieves CE-IVD milestone for severe bacterial pneumonia assay, doubles revenue for 2017 in Q4Accelerate Diagnostics achieves CE-IVD milestone for severe bacterial pneumonia assay, doubles revenue for 2017 in Q4
finance.yahoo.com - January 10 at 10:50 AM
Accelerate Diagnostics (AXDX) Rating Increased to Hold at Zacks Investment ResearchAccelerate Diagnostics (AXDX) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - January 8 at 6:52 PM
Zacks: Accelerate Diagnostics Inc (AXDX) Given $26.50 Average Price Target by AnalystsZacks: Accelerate Diagnostics Inc (AXDX) Given $26.50 Average Price Target by Analysts
www.americanbankingnews.com - January 8 at 9:40 AM
Stocks To Watch: Accelerate Diagnostics Sees RS Rating Rise To 83Stocks To Watch: Accelerate Diagnostics Sees RS Rating Rise To 83
finance.yahoo.com - January 6 at 8:48 AM
Accelerate Diagnostics to Present at the 36th Annual JP Morgan Healthcare Conference in San Francisco - GlobeNewswire (press release)Accelerate Diagnostics to Present at the 36th Annual JP Morgan Healthcare Conference in San Francisco - GlobeNewswire (press release)
globenewswire.com - January 4 at 3:28 PM
Presbia (LENS) vs. Accelerate Diagnostics (AXDX) Head-To-Head ReviewPresbia (LENS) vs. Accelerate Diagnostics (AXDX) Head-To-Head Review
www.americanbankingnews.com - January 2 at 7:14 PM
Stocks To Watch: Accelerate Diagnostics Sees Relative Strength Rating Jump To 82Stocks To Watch: Accelerate Diagnostics Sees Relative Strength Rating Jump To 82
finance.yahoo.com - December 27 at 1:33 PM
Accelerate Diagnostics, Inc. (AXDX)Accelerate Diagnostics, Inc. (AXDX)
finance.yahoo.com - December 20 at 9:30 AM
Short Interest in Accelerate Diagnostics Inc (AXDX) Declines By 8.6%Short Interest in Accelerate Diagnostics Inc (AXDX) Declines By 8.6%
www.americanbankingnews.com - December 18 at 4:36 PM
BTIG Research Lowers Accelerate Diagnostics (AXDX) to NeutralBTIG Research Lowers Accelerate Diagnostics (AXDX) to Neutral
www.americanbankingnews.com - December 17 at 9:24 AM
Technical Perspectives on TrovaGene, Accelerate Diagnostics, NeoGenomics, and Exact SciencesTechnical Perspectives on TrovaGene, Accelerate Diagnostics, NeoGenomics, and Exact Sciences
www.bizjournals.com - December 14 at 9:41 AM
ETFs with exposure to Accelerate Diagnostics, Inc. : December 12, 2017ETFs with exposure to Accelerate Diagnostics, Inc. : December 12, 2017
finance.yahoo.com - December 12 at 3:28 PM
Accelerate Diagnostics Hits 80-Plus Relative Strength Rating BenchmarkAccelerate Diagnostics Hits 80-Plus Relative Strength Rating Benchmark
finance.yahoo.com - December 8 at 3:28 PM
Zacks: Analysts Set $26.50 Target Price for Accelerate Diagnostics Inc (AXDX)Zacks: Analysts Set $26.50 Target Price for Accelerate Diagnostics Inc (AXDX)
www.americanbankingnews.com - December 6 at 5:30 PM
Stocks With Rising Relative Strength: Accelerate DiagnosticsStocks With Rising Relative Strength: Accelerate Diagnostics
finance.yahoo.com - December 6 at 3:28 PM
Accelerate Diagnostics Meets 80-Plus Relative Strength Rating BenchmarkAccelerate Diagnostics Meets 80-Plus Relative Strength Rating Benchmark
finance.yahoo.com - December 1 at 3:32 PM
ETFs with exposure to Accelerate Diagnostics, Inc. : November 30, 2017ETFs with exposure to Accelerate Diagnostics, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 3:28 PM
First Week Of January 2018 Options Trading For Accelerate Diagnostics (AXDX)First Week Of January 2018 Options Trading For Accelerate Diagnostics (AXDX)
www.thestreet.com - November 21 at 4:49 PM
Zacks: Brokerages Set $29.50 Target Price for Accelerate Diagnostics, Inc. (AXDX)Zacks: Brokerages Set $29.50 Target Price for Accelerate Diagnostics, Inc. (AXDX)
www.americanbankingnews.com - November 21 at 3:16 PM
ETFs with exposure to Accelerate Diagnostics, Inc. : November 20, 2017ETFs with exposure to Accelerate Diagnostics, Inc. : November 20, 2017
finance.yahoo.com - November 20 at 5:32 PM
Accelerate Diagnostics, Inc. (AXDX) Director Buys $121,000.00 in StockAccelerate Diagnostics, Inc. (AXDX) Director Buys $121,000.00 in Stock
www.americanbankingnews.com - November 20 at 4:43 PM
Accelerate Diagnostics (AXDX) Appoints Dr. Charles Watts to BoardAccelerate Diagnostics (AXDX) Appoints Dr. Charles Watts to Board
www.streetinsider.com - November 17 at 3:59 PM
Accelerate Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : AXDX-US : November 17, 2017Accelerate Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : AXDX-US : November 17, 2017
finance.yahoo.com - November 17 at 9:54 AM
Insider Buying: Accelerate Diagnostics, Inc. (AXDX) Director Acquires 20,000 Shares of StockInsider Buying: Accelerate Diagnostics, Inc. (AXDX) Director Acquires 20,000 Shares of Stock
www.americanbankingnews.com - November 16 at 4:48 PM
Accelerate Diagnostics (AXDX) Appoints Dr. Charles Watts to Board - StreetInsider.comAccelerate Diagnostics (AXDX) Appoints Dr. Charles Watts to Board - StreetInsider.com
www.streetinsider.com - November 16 at 4:35 PM
Accelerate Diagnostics Welcomes Dr. Charles Watts to its Board of DirectorsAccelerate Diagnostics Welcomes Dr. Charles Watts to its Board of Directors
finance.yahoo.com - November 16 at 4:35 PM
Accelerate Diagnostics to Present at the 29th Annual Piper Jaffray Healthcare Conference in New York CityAccelerate Diagnostics to Present at the 29th Annual Piper Jaffray Healthcare Conference in New York City
finance.yahoo.com - November 16 at 11:44 AM
Accelerate Diagnostics (AXDX) in Focus: Stock Moves 6.7% HigherAccelerate Diagnostics (AXDX) in Focus: Stock Moves 6.7% Higher
finance.yahoo.com - November 16 at 11:44 AM
Accelerate Diagnostics, Inc. (AXDX) Director Buys $379,600.00 in StockAccelerate Diagnostics, Inc. (AXDX) Director Buys $379,600.00 in Stock
www.americanbankingnews.com - November 15 at 8:22 PM

SEC Filings

Accelerate Diagnostics (NASDAQ:AXDX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Accelerate Diagnostics (NASDAQ:AXDX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Accelerate Diagnostics (NASDAQ AXDX) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.